Table 3. Effects of continuous positive airway pressure in patients with nasal polyposis and in control subjects.
| Characteristics (mean ± SD) | Control Group | NP Group | |||||
|---|---|---|---|---|---|---|---|
| Pre-CPAP | Post-CPAP | p * | Pre-CPAP | Post-CPAP | p * | ||
| Nasal obstruction symptoms | VAS | 2.66 ± 1.8 | 4.55 ± 2.6 | < 0.01 | 4.75 ± 2.43 | 5.25 ± 3.06 | 0.72 |
| NOSE | 2.74 ± 1.85 | 5.00 ± 3.00 | < 0.01 | 6.62 ± 2.97 | 6.13 ± 2.59 | 0.73 | |
| Nasal patency | AR | 11.98 ± 3.6 | 10.08 ± 2.4 | < 0.01 | 5.06 ± 2.83 | 4.36 ± 1.78 | 0.17 |
| PNIF | 127.15 ± 50.2 | 112.37 ± 54.8 | < 0.01 | 117.5 ± 53.92 | 92.5 ± 43.99 | 0.04 | |
| Nasal endoscopic evaluation | Meltzer Score | — | — | — | 6.08 ± 1.68 † | 5.42 ± 1.88 † | 0.04 ‡ |
Abbreviations: CPAP, continuous positive airway pressure; NOSE, nasal obstruction symptoms evaluation; NP, nasal polyposis; PNIF, peak nasal inspiratory flow; SD, standard deviation; VAS, visual analog scale.
* p -values for comparisons within-group; † Meltzer score for both nasal cavities. ‡ Binomial sign test.